Navigation path

Additional tools



    Profile of registrant

Genzyme a SANOFI Company

Identification number in the register: 2946627525-90
Registration date: 17/10/2008 14:57:50

The information on this entity was last modified on: 25/04/2015 18:08:35
The date of the last annual update was: 26/03/2015 15:05:33
Next update due latest on: 26/03/2016

    Registrant : Organisation or self-employed individual

Genzyme a SANOFI Company

Genzyme

Corporation

    Section of registration

II - In-house lobbyists and trade/business/professional associations

Companies & groups

    Contact details

Kendall Street, 500
Cambridge MA 02142
UNITED STATES

(+1) 617 252 7500

rue de la science 14
Brussels 1040
BELGIUM

(+32) 25483857

    Person with legal responsibility

Mr  David Meeker

CEO

    Person in charge of EU relations

Ms  Vinciane Pirard

Sr Director Public Affairs

    Goals / remit

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.

global

    Specific activities covered by the Register

rare disease policies, pharmaceutical dossiers and use of biotechnology in health care

in particular in the context of and related to:
- REGULATION (EC) No 141/2000 of 16 December 1999 on orphan medicinal products

- COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS on Rare Diseases: Europe's challenges - Brussels, 11.11.2008 COM(2008) 679 final
- EU Net HTA Joint action
- EUCERD Joint Action
- IMI


 

No

No

Expert Group on Rare diseases

No

No

To facilitate access to treatments for high, unmet medical need especially rare genetic diseases and multiple sclerosis.
To support all aspects supporting Europe’s Innovation and Research & Development activities in healthcare.

    Number of persons involved in the activities described in the box above

50%: 1   25%: 2

3

1

    Persons accredited for access to European Parliament premises

No accredited persons

    Fields of interest

  • Economic and Financial Affairs
  • Enterprise
  • Internal Market
  • Public Health
  • Research and Technology

    Membership and affiliation

Member of BIO (US), PhARMA (US), EFPIA (EU), EBE (EU) & EuropaBio (EU)

    Financial data

01/2014  -  12/2014

400,000 € - 499,999 €

No funding received from the EU institutions during the last closed financial year.

    Code of conduct

By its registration the organisation has signed the Transparency Register Code of Conduct.